Expert Analysis

Breast Cancer Panel

Source: CCO Independent Conference Coverage of the 2008 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Breast Cancer Panel

Program Director: Ramaswamy Govindan, MD

Faculty:

William J. Gradishar, MD, FACP
Clifford A. Hudis, MD
Kathy D. Miller, MD

Christy Russell, MD

CREDIT INFORMATION

Release Date: August 07, 2008

Expiration Date: August 06, 2009

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing contact hours

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data from recent studies regarding current standards of care for the use of tamoxifen
Describe new data on the use of the investigational agents pertuzumab and pazopanib in the treatment of patients with HER2-positive metastatic breast cancer
Discuss the integration of treatment strategies involving multiple agents for the clinical management of patients with breast cancer

Topics covered include:

Improved Disease-Free Survival With Zoledronic Acid in Premenopausal Women With Endocrine-Responsive Breast Cancer
Epirubicin/Cyclophosphamide Followed by Paclitaxel Plus Gemcitabine as Adjuvant Therapy in Early-Stage Breast Cancer Patients
Standard Adjuvant Chemotherapy vs Capecitabine in Older Breast Cancer Patients
Effects of Surgical Year and Preoperative Breast Magnetic Resonance Imaging on Mastectomy Rate
Prognostic Value of Vitamin D Levels in Women With Newly Diagnosed Local or Regional Breast Cancer
Effect of Zoledronic Acid on Bone Mineral Density in Premenopausal Women With Chemotherapy-Induced Ovarian Failure
Efficacy of 10-Year Adjuvant Tamoxifen Compared With the Standard 5-Year Treatment
Molecular Changes in Primary Breast Cancer to Relapsed/Metastatic Breast Cancer
Lapatinib Plus Trastuzumab vs Lapatinib Alone in Progressive HER2-Positive Metastatic Breast Cancer
Trastuzumab and Pertuzumab in Patients With Progressive HER2-Positive Metastatic Breast Cancer
Continued Trastuzumab Plus Capecitabine Following Disease Progression With Trastuzumab Therapy in Patients With HER2-Positive Metastatic Breast Cancer
Lapatinib Plus Pazopanib vs Lapatinib Alone in HER2-Positive Metastatic Breast Cancer
The AVADO Trial: Bevacizumab Plus First-Line Docetaxel in Patients With HER2-Negative Metastatic Breast Cancer
Concluding Remarks

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.